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Abstract 
 
A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR 
therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR 
therapy in some cancers, it has been suggested that screening for KRAS and BRAF 
mutations in RCC may be a promising strategy to identify patients who might respond to 
EGFR-targeted therapy. The aim of this study was to investigate the mutation status of 
EGFR, KRAS and BRAF in RCC patients. Renal tumors and normal renal samples from 
forty-eight patients who underwent radical or partial nephrectomy for kidney cancer were 
used in this study. Histological classification of the tumors was performed according to 
International Union against Cancer (UICC) / American Joint Committee on Cancer (AJCC) 
classification. Seventeen patients (48%) had clear-cell RCC, 7 (20%) had chromophobe RCC, 
and 11 patients (32%) had papillary RCC. DNA isolated from the samples was subjected to 
melting curve mutation analysis for EGFR, BRAF and KRAS using ABI-3130 DNA 
sequencer. DNA sequencing analysis of RCC samples, when compared with morphologically 
normal matched regions, did not show any exon mutations. Our results do not support the 
notion that EGFR, KRAS and BRAF might be mutated in RCC. Copyright: The Authors. 
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INTRODUCTION 
 
 
Renal cell carcinoma (RCC) constitutes 3% 
of all adult malignancies (1). According to 
Surveillance, Epidemiology, and End 
Results (SEER) data, the annual increase 
in RCC incidence is 2.5-3%, as we have 
started to use modern imaging methods 
more frequently since 1970s  (2). Although 
60% of new diagnoses are coincidental, 
25% of the patients are metastatic during 
the diagnosis (3). Radical nephrectomy or 
nephron sparing surgery is the standard 
treatment for localized RCC, while 30% of 
the patients experience recurrence after the 
surgery (3). Despite the tremendous 
improvements in our understanding of the 
molecular mechanisms of RCC, and the 
introduction of many novel multi-tyrosine 
kinase inhibitors in clinical practice for the 
treatment of RCC the five-year survival of 
metastatic patients continues to be less 
than 10%. There is a need for a better 
understanding of the molecular 
mechanisms of RCC and the discovery of 
more efficient therapeutics for the 
management of metastatic RCC. The 
epidermal growth factor receptor (EGFR), a 
transmembrane tyrosine kinase receptor of 
the Erb family, is overexpressed in both 
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primary and metastatic RCC (4-6) 
suggesting the potential of anti-EGFR 
agents as therapeutics for the treatment of 
RCC. While anti-EGFR therapy 
demonstrated effective anti-tumoric activity 
in laboratory settings (7, 8), clinical trials 
demonstrated a very low objective response 
(9). Of the 88 patients treated with ABX-
EGF, one complete, two partial, and two 
minor responses were observed (9). While 
the reasons for these disappointing results 
are not clear, it is possible that mutations 
of KRAS and BRAF are involved. This 
notion stems from the fact that, in 
colorectal cancer,  mutations of 
KRAS/BRAF genes, which are integral part 
of the EGFR signaling pathway make EGFR 
inhibitors ineffective (10, 11). On the 
contrary, a case report demonstrates that 
EGFR mutations could sensitize patients to 
anti-EGFR therapy (12). Therefore, 
screening for EGFR, KRAS and BRAF 
mutations in RCC may be a promising 
strategy to identify patients who might 
respond to EGFR-targeted therapy.  The 
present study aims to identify EGFR,   
KRAS and BRAF mutations in RCC.  
 
MATERIALS AND METHODS 
 
Patient Selection  
 
After obtaining local ethics committee 
approval, RCC and matched normal 
samples from 48 patients who underwent 
radical or partial nephrectomy for kidney 
cancer were evaluated between June 2009 
and June 2011 at the University of 
Gaziantep, Department of Urology, Turkey. 
Thirteen patients who had benign and 
ureteral carcinoma according to the 
pathological results were excluded from the 
study. The samples from the remaining 35 
patients were used for further study. 
Portion of the samples were formalin-fixed 
and processed for histology and the 
remaining were stored at -80oC until use.  
 
Histology 
 
Three micron sections of the formalin-fixed 
kidney samples were stained with 
hematoxyline  and eosine and the tumor 
grade was determined  according to 
International Union against Cancer (UICC) 
/ American Joint Committee on Cancer 
(AJCC) 2009 TNM classification, whereas 
tumor nuclear grading was performed 
according to the Fuhrman grading system 
by a qualified Pathologist.  
 
Mutation Detection 
 
DNA from kidney samples that had been 
stored at -80oC (30-50 mg tissue) were 
isolated using Roche High Pure Polymerase 
Chain Reaction (PCR) Template Preparation 
Kit (Catalogue Number: 11 796 828 001) 
following the protocol of the supplier. DNA 
samples were stored at -20°C until further 
use. DNA sequencing was performed on an 
ABI 3130 DNA sequencing analysis 
instrument. The target area was amplified 
by PCR using primers specific to EGFR, 
KRAS, and BRAF (Table 1).  
 
The primers were designed specifically for 
the most mutation presenting regions of 
EGFR, BRAF and KRAS genes. These 
regions contained exons 18, 19, 21 for 
EGFR, exons 11, 15 for BRAF and exons 1, 
2 for KRAS genes (13-15).  The PCR 
conditions were the same for all PCR 
reactions. PCR products were visualized 
with agarose gel electrophoresis. After 
detecting the optimal size of PCR product, 
DNA sequencing was performed using 
BigDye® Terminator v1.1 Cycle Sequencing 
Kit (Applied Biosystem, SKU#4337450).  
 
The PCR mixture was kept at 96°C for 1 
minute. Then, PCR was carried out with 25 
cycles consisting of following steps: 10 
seconds at 96°C, 5 seconds at 50°C, and 4 
minutes at 60°C. Samples were kept at 4°C 
until they were placed in the instrument. In 
automated DNA sequencing, PCR products 
were loaded into the instrument after a 
clean-up step through Sephadex. To do 
this, 1 g of Sephadex was dissolved in 14 
ml of ultrapure water, and 600 μl of this 
solution was transferred to the columns. 
After centrifugation at 2000xg for 2 
minutes, Sephadex-containing columns 
were transferred to other tubes, and 10 μl 
of PCR product was added on Sephadex. 
Centrifugation was performed at 2000xg for 
2 minutes. Following centrifugation, the 
products at the bottom of the tube were 
subjected to DNA sequencing by Sanger 
dye-terminator sequencing method. Each 
dideoxynucleotide in the DNA sequence 
analysis was labelled with a different 
fluorescence dye. Amplified DNA fragments 
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      Table 1. PCR primers and product lengths of EGFR, BARF and KRAS 
 
Gene Exon  Primer sequences 
Product 
length (bp) 
EGFR 
18 
Forward GTGAGGGCTGAGGTGACC 
186 
Reverse TGTGCCAGGGACCTTACC 
19 
Forward TGCCAGTTAACGTCTTCC 
155 
Reverse CACAGCAAAGCAGAAACTC 
21 
Forward TCTTCCCATGATGATCTGTC 
225 
Reverse GACCTAAAGCCACCTCCT 
BRAF 
11 
Forward TGTTTGGCTTGACTTGAC 
176 
Reverse CACCACATTACATACTTACC 
15 
Forward TACTGTTTTCCTTTACTTAC 
165 
Reverse TAGCCTCAATTCTTACCA 
KRAS 
1 
Forward GGCCTGCTGAAAATGACTGA 
162 
Reverse GTCCTGCACCAGTAATATGC 
2 
Forward CTGTAATAATCCAGACTGTG 
151 
Reverse TCCCCAGTCCTCATGTACTG 
 
 
were migrated through a “gel matrix”, 
which were loaded in capillaries, and 
detected by an instrument capable of 
recognizing fluorescent dyes. 
 
RESULTS 
 
Nineteen male and 16 female patients (35 
patients in total) who had RCC were 
included in the study. The mean age of the 
patients was calculated as 59.31±12.52 
(15-77) years. None of the patients were in 
an occupational group that might play a 
role in kidney cancer etiology. History of 
smoking was present in ten male patients 
(52.6%) and in four female patients (25%). 
The mean body mass index was 28.31 ± 
3.45 (21-33) kg/m2. According to 
histopathological UICC and AJCC 
classification systems, 17 patients (48%) 
had clear-cell RCC, 7 patients (20%) had 
chromophobe cell RCC, and 11 patients 
(32%) had papillary RCC. According to 
2009 TNM staging of the tumors, 11 
patients (31%) were T1a, 8 patients (23%) 
were T1b, 3 patients (8%) were T2, 9 
patients (26%) T3a, and 4 patients (12%) 
T3b. Twenty-three patients (65%) were 
evaluated as N0, 8 were (23%) N1, and 4 
patients were (12%) N2. According to the 
Fuhrman grading system, 3 patients (8%) 
were Grade 1, 15 patients (43%) were 
Grade 2, and 17 patients were (49%) Grade 
3 (Table 2).   DNA sequencing analysis of 
cancer samples and normal tissues did not 
show any exon mutations in the EGFR, 
BRAS, and KRAS pathway (data not 
shown).  
 
DISCUSSION 
 
BRAF and KRAS belong to the RAF proto-
oncogene serine / threonine-protein kinase 
(c-RAF) gene family and their over 
expression or mutations trigger abnormal 
cell proliferation. EGFR is believed to be 
responsible for cell proliferation during 
carcinogenesis (16). Kamai et al. (17) 
evaluated the association of parathyroid 
hormone-related protein (PTHrP) and KRAS 
in RCC. Of the 51 patients, serum PTHrP 
and mRNA expression of KRAS were 
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                      Table 2. Characteristics of patient samples
RCC subtype                %               Number of samples 
 
Clearcell RCC                  48%                              (17/35) 
Papillary RCC                  32%                              (11/35) 
Chromophobe RCC          20%                              (7/35) 
TNM 
 
T1a                                   31%                             (11/35) 
T1b                                   23%                             (8/35) 
T2                                     8%                               (3/35) 
T3a                                   26%                             (9/35) 
T3b                                   12%                             (4/35) 
 
N0                                    65%                             (23/35) 
N1                                    23%                             (8/35) 
N2                                    12%                             (4/35) 
Fuhrman’s Classification 
 
Grade 1                            8%                               (3/35) 
Grade 2                            43%                             (15/35) 
Grade 3                            49%                             (17/35) 
 
significantly high in 7 patients (17). Also, 
there was a correlation between high KRAS 
expression and PTHrP-induced 
hypercalcemia.  However, the mutation 
status of KRAS was not studied. Kozma et 
al. (18) analyzed 36 RCC samples for c-myc 
and KRAS amplification. Three samples 
(8.3%) showed c-myc, and 6 samples 
(16.6%) displayed KRAS amplifications.  
The authors also reported that the 
amplifications correlated with tumor grade 
and size but not with lymph node 
involvement.  In a comprehensive analysis 
of 121 RCC samples, KRAS and BRAF did 
not reveal any mutations (19). In a 
multicenter study, Szymanska et al. (20) 
investigated the correlation between TP53 
(exons 5-9), EGFR (exons 18-21) and KRAS 
(codon 12) mutation and Von Hippel-
Lindau (VHL) gene in tissue samples 
derived from 361 RCC (334 clear-cell 
carcinomas) patients. The authors observed 
TP53 mutation in 4% of clear-cell 
carcinoma subtypes, which was 
independent of VHL mutations. EGFR and 
KRAS mutations were not detected in any 
patients. The authors concluded that TP53, 
KRAS, or EGFR mutations do not have a 
major contribution to RCC development, 
provided that the VHL gene is not 
inactivated (20). Furthermore, Sakaeda and 
colleagues reported no mutations of EGFR 
in a cohort of Japanese patients (21).  We 
studied EGFR, BRAF and KRAS mutation 
in a Turkish cohort, and did not find any 
mutations, corroborating previous findings. 
Screening for EGFR, KRAS and BRAF 
mutations in RCC is unlikely to be a 
promising strategy to identify patients who 
might respond to EGFR-targeted therapy.   
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